Akari Therapeutics — Third Quarter 2026 Earnings Summary

Akari Therapeutics initiated GLP toxicology studies for its lead candidate AKTX-101, a TROP2-targeted antibody-drug conjugate utilizing the novel PH1 payload, to support a planned Phase 1 clinical trial in mid-2027. New preclinical data demonstrated that AKTX-101 exhibited significant tumor growth inhibition in urothelial cancer models resistant to existing therapies like Padcev and Trodelvy. The company reported third-quarter 2026 financial results showing $5.7 million in cash, a net loss of $4.8 million, and the full repayment of $0.7 million in convertible notes. Additionally, Akari strengthened its business development capabilities with the appointment of a new Chief Business Officer and expanded its intellectual property portfolio with a new patent application covering PH1's RNA splicing modulation mechanisms.